Nymox reports favorable safety monitoring committee results for trial Nymox Pharmaceutical provided an update on its Phase 3 NX02-0020 repeat injection U.S. study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The company said the recent Safety Monitoring Committee meeting was favorable and indicated no significant safety concerns for the trial to date. Patient recruitment and trial activities for this U.S. Phase 3 Study are nearing completion at urology investigative sites throughout the U.S.
News For NYMX From The Last 14 Days
Check below for free stories on NYMX the last two weeks.
Subscribe for More Information